Taken all results together, the proposed molecular mechanism for MLN in AD treatment is that MLN could activate PP2A and SIRT1/AMPK/mTOR signaling-mediated autophagy to reduce Tau phosphorylation. This evidence concerns the gene SIRT1 and Alzheimer disease.